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Summary: Pretreatment and serial posttreatment carcino embryonic antigen (CEA) serum levels were studied with
respect to the course of disease in 222 patients with colorectal cancer. The CEA values during the subsequent six
years were expressed in actuarial or cumulative plots in relation to tumour-free period, time of diagnosis of recurrence
and other parameters.
The pretreatment CEA value was highly significant but gave no more prognostic information than the Dukes classi-
fication. The pretreatment CEA had prognostic significance only in inoperable patients. Elevated pretreatment CEA
did not exclude the possibility of curative treatment. Normalization of CEA after resection did not indicate com-
pleteness of cure.
In patients with local or distant recurrences CEA occasionally rose before recurrences became clinically apparent.
Positive lead time was 0-625 days.
However, in about 40% of the patients clinical diagnosis of recurrence preceded a rise of CEA. Maximal negative lead
time was 585 days. Statistically, recurrence without a rise of CEA was exceptional. The results stronly suggest that
serial CEA determinations cannot replace physical examination and follow-up.
Prognostischer Wert der CEA Bestimmung beim Carcinom des Colon oder Rectum: Eine statistische Untersuchung
Klinische Bewertung des carcinoembryonalen Antigens, 5. Mitteilung
Zusammenfassung: Die Ergebnisse der Bestimmung des carcinoembryonalen Antigens (CEA) bei 222 Patienten mit
Carcinom des Colon oder Rectum mit einer Überwachungszeit von bis zu 6 Jahren wurden statistisch bearbeitet.
Die Ergebnisse zeigen, daß dem präoperativ bestimmten CEA signifikant prognostische Bedeutung zukommt. Der
präoperative CEA-Wert hat aber keine größere Aussagekraft hinsichtlich der Voraussage einer Rezidivierung oder
Metastasierung als die Klassifizierung n^ch Dukes.
Die Behandlung der Patienten mit erhöhtem CEA ist sinnvoll, selbst bei CEA-Werten > 20,0 Mg/1. Ein Abfallen des
CEA in den Normalbereich ist kein Beweis für Radikalität der primären Behandlung.
Bei 40% der Patienten stieg der CEA-Wert während der Verlaufskontrolle, nachdem Metastasen oder Lokalrezidive
festgestellt wurden. Aus statistischer Sicht gilt, daß bei allen Rezidiven der CEA-Wert schließlich ansteigt, daß aber
ein normaler CEA-Wert während der Verlaufskontrolle die Anwesenheit eines sich entwickelnden Rezidivs nicht aus-
schließt. Fortlaufende CEA-Bestimmungen können übliche klinische Untersuchungsmethoden nicht ersetzen.
Introduction
precise definition of the clinical role of carcino^mbry- especially concerning the course of CEA in recurrence,
onic antigen (CEA) in colorectal cancer is possible only Three Problems *" *****to be solved:
when statistical analyses of CEA data in correlation with 1. does preoperative CEA have additional prognostic sig-
clinical data in long term follow-up studies are available. nificance over histological staging of tumour spread or
There are in fact relatively few studies (1,2,3) based on over other clinical data obtained immediately after pri-
long term follow-up with complete statistical work up, mary treatment?
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2. what is the distribution of lead times of CEA before
and after objective evidence of recurrence?
3. what is the minimum time for routine follow-up by
CEA assays necessary to detect recurrence?
The present report is a statistical analysis of the associa-
tion of CEA before and after primary treatment with the
course of colorectal cancer, in an attempt to answer the
above questions. The report concerns 222 patients fol·
lowed for one to six years. We feel that this report may
contribute to final conclusions about the clinical value
of CEA.
Patients and Methods
The entire patient population studied consisted of. 129 patients
with histologically documented coIonic cancer and 93 patients
with histologically documented cancer of the rectum. The median
age was 65 years (30-95 years). The patients of both categories
were treated as one group. Two hundred and five patients under-
went surgery as primary treatment. In 189 of these patients the
surgical treatment was intended to be curative. In the remaining
patients surgery was palliative because of distant metastases prior
to surgery.
Tumour spread was judged according to Dukes classification (4,
5) in 188 patients. Out of these 17 had Dukes A, 99 had Dukes
B and 72 had Dukes C lesions. Figure 1 shows the association
with rate of recurrence in our patients. Nineteen patients receiv-
ed radiation therapy as primary treatment either because they
refused surgery or because they were considered inoperable. In-
dications of residual tumour after surgery were
(a) cut surfaces of resection material not free of tumour or
(b) tumour remaining in situ after resection or
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Fig. 1. Actuarial plot of recurrence-free periods for patients di-
vided into Dukes's A, B and C groups. The ordiriate indi-
cates percentage of patients remaining recurrence-free
after primary therapy. The numbers between parentheses
indicate number of patients involved at zero time (time
of primary treatment). The numbers below indicate num-
ber of patients at risk at the corresponding time interval
post therapy. P = ÉÏ"9.
Indications of residual tumour after radiation therapy or of recur-
rent disease were: observation of tumour at relaporotomy or co-
lonoscopy, positive findings of liver, or bone scintigram, chest,
skeletal or colon X-ray pictures. Other indications were provided
by intravenous pyelogram or computer tomography.
Pretreatment CEA values were available in 193 patients. There
was no correlation between age and pretreatment CEA (p = 0.15).
After primary treatment the patients had routine physical exami-
nations every two to six months. Blood for the CEA test was
taken at every examination.
During our study 70 patients out of the group which underwent
curative resection showed clinical evidence of recurrence. Among
these, local recurrence was demonstrated in 18 patients, meta-
stases in 52 patients.
The CEA assay
CEA was measured in duplicate by a radio immunoassay as des-
cribed in full earlier (6). Briefly, the sample is incubated over-
night with goat anti-CEA-antiserum and labeled CEA. The addi-
tion of the latter is delayed for some hours. The degree of inhi-
bition was measured by the radioactivity in the residue, taking
the radioactivity in the absence of unlabeled CEA as 100%. A
standard dilution was constructed by adding 16 different known
amounts of CEA (from zero to 75.0 Mg/1) in human normal
serum (from nonsmokers), thus providing sufficient points for
the construction of the inhibition curve. The CEA and the goat
antiserum were prepared in our laboratory. The lower limit of
sensitivity was 3.0 Mg/1. Samples resulting in a percentage of
bound radioactive CEA lower than 25% over BQ were re-assayed
after appropriate dilution with human normal serum.
Generally, a batch of normal serum was used for three weeks and
replaced at the end of this period by a batch taken from another
healthy non-smoking donor. However, healthy persons can have
different serum CEA values and the change from one batch of
normal serum to another may introduce a shift in the measured
CEA values. It is evident that for long term follow-up studies
such alterations in CEA values must be avoided in a controlable
way.
We have solved this problem by introducing a 'standard ñïïÃ.
The reader is referred to I.e. (6) for further details.
In addition, within every run 4-6 different serum pools were in-
corporated at various positions scattered throughout the whole
series. The range of each pool had been determined by calcula-
tion of the mean value and the 95 % confidence limits obtained
from results within at least 30 runs. New serum pools were only
incorporated as controls after their range was established. By
these measures sufficient reproducibility for a long period was
obtained, which is a prerequisite for long term follow-up studies.
The results from the patients' sera were not accepted if more than
one of the serum pools showed values outside established ranges.
Comparison of our method with the (Abbott) kit showed a corre-
lation coefficient r = 0.962. (Calculated regression line: y (our
method) = 1.04 ÷ (Abbott kit) - 0.67).
Statistical analysis
Statistical analysis was done on data accrued over the period be-
fore primary treatment till recurrence was clinically manifest, or
in recurrence-free patients till termination of the study. Thus,
the terms pretreatment and posttreatment refer to primary treat-,
ment. The relationship between CEA pretreatment values and
prognosis (relapse) was analyzed using the method of Kaplan &
Meier (7) to produce the graphs, and the test of Mantel (8) with
the natural numbers as scores for the CEA categories to calculate
the p-values. As CEA pretreatment values the last CEA before
primary treatment was chosen, but only if this measurement oc-
curred witfcin thirty days before treatment.
To analyse the relationship between serial CEA values after treat-
ment and prognosis, the following definitions have been used. A
CEA fall was defined by the occurrence of at least two subse-
quent CEA values satisfying the following criterion: < 5.0 Mg/1
if the CEA pretreatment value was between 5.0 - 9,.$ Mg/1, at least
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5 Mg/1 lower than the CEA pretreatment value if this was between
10.0-19.9 Mg/1 or at least 10.0 Mg/1 lower than the CEA Ore-
treatment value if this was £ 20.0 Mg/l. Of course, if the CEA pre-
treatment value was normal, no CEA decrease was observed.
CEA lowest point and lowest value
If a CEA decrease occurred the CEA lowest point was defined
by the time at which during this decrease the highest of any two
subsequent CEA measurements reached a minimum. This mini-
mum was termed the CEA lowest value. If no CEA decrease oc-
curred, the CEA lowest value was equated to the CEA pretreat-
ment value.
CEA rise
A CEA rise was said to occur when at least two subsequent CEA
measurements satisfying the following criterion were noted: if
the CEA lowest value was < 5.0 Mg/I the subsequent CEA values
should be at least 5.0 Mg/1; if the lowest value was 5.0 - 9.9 Mg/1
or 10.0 -19.9 Mg/1 the subsequent values should be at least 5.0
Aig/1 higher; if the lowest value was > 20.0 Mg/1 the subsequent
value should be at least 10.0 Mg/1 higher.
CEA no fall
If neither a CEA decrease nor a CEA increase was observed, the
CEA values were termed 4no fair. These definitions were used so
as to minimize on the one hand the influence of occasional out-
lying points and to retain on the other hand as much resolution
as possible.
The statistical significance of the relationship between CEA in-
crease and prognosis was analyzed using a method given by
Clayton (9) in a different context. This method can be seen to
be a generalization of the logrank test: for each time point at
which a CEA increase occurred, the prognosis of the patient
whose CEA increase did occur on that time was compared, using
the logrank test, with the prognosis of patients who, up to that
time, had not undergone a CEA increase; these separate compari-
sons were then combined using the Mantel-Haenszel procedure
(10). In the case of relapse as a prognostic parameter, a CEA in-
crease occurring after the relapse was discounted in this proce-
dure.
To get a graphic impression of the relationship between CEA in-
crease and prognosis for those patients who, at some time during
their follow-up, showed a CEA increase, the intervals between
time of CEA increase and time of relapse have been displayed in
the way generally used for survival times. In the same graph com-
parable curves are then given for patients who, within specified in-
tervals from treatment, did not show a CEA increase, measuring
relapse time from the end of the specified interval.
Results
Table 1 gives the distribution of CEA pretreatment levels
for the different groups according to Dukes.
Association of pretreatment CEA with recurrence
Figure 2 is an actuarial plot showing the association of
the pretreatment CEA value with subsequent develop-
ment of disease (local recurrence or distant metastases)
Tab. 1. Pretreatment CEA levels and extent of tumour in 164 pa-
tients with colon or rectum cancer.
CEA(Mg/l) <5.0 5.0-9.9 10.0-19.9 > 20.0
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Fig. 2. The association of pretreatment CEA with recurrence in
all patients. See legend to figure I and section Patients
and Methods for explanation of presentation.
P=0 .37X ÉÏ"4.
in all patients. As can be seen from the intersection of
the vertical axis a fraction of approx. 0.30 of the patients
with CEA levels ̂  20.0 Mg/1 had residual tumour after
primary treatment. For patients with pretreatment CEA
values between 10.0-19.9 Mg/1 and < 10.0 Mg/1 these
figures are 0.18 and 0.05 respectively. The prognostic
significance of pretreatment CEA is evident: patients with
CEA exceeding 10.0 Mg/1 developed recurrent disease
earlier and at a higher rate than those in whom CEA
levels were below 5.0 ^g/1 or between 5.0 and 9.9 Mg/1.
(The differences between the latter groups were not
significant).
Association of pretreatment CEA with recurrence taking
posttreatment clinical data into consideration
The patients presented above constituted a heterogene-
ous group in the sense that 37 patients, i.e. a fraction of
0.16, proved to have residual tumour after primary treat-
ment (see tab. 2). It is interesting to note that after
discarding the patients with residual tumour from the
analysis the differences between the groups based on their
pretreatment CEA values below 19.9 Mg/1 and ̂  20.0 Mg/1
scarcely reached a significant level (fig. 3). Thus, if clinical
data obtained during or immediately after primary treat-
ment became available the prognostic value of pretreat-
ment CEA diminished sharply. The prognostic significance
of pretreatment CEA was further diminished if the Dukes
stage was taken into account. Figure 4 shows that tu-
mour-free periods of Dukes B patients were not signifi-
cantly different if grouped according to different levels
of their pretreatment CEA values. Similar results were
found in patients with Dukes C lesions (data not shown).
Thus the assessment of CEA prior to surgery provides no
additional prognostic information over staging according
to Dukes.
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^j^^ Tab. 2. Range of CEA values before and after primary therapy
%xO^\. CEA Pretreatment Residual No, of
V>ZX^ [jig/l] ln ' CEAfag/l) tumour patients
V *' :'V^?\ _5-10 (41)
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Fig. 3. The association of pretreatment CEA with" recurrence in
patients without residual tumour. See legend to figure 1
and section Patients and Methods for explanation of pre-






















Fig. 4. The association of pretreatment CEA with recurrence in
patients with Dukes B lesions without metastases. See le-
gend to figure 1 and section Patients and Methods for ex-
planation of presentation. P = 0.30.
Fall of posttreatment CEA in patients with residual
tumour
Table 2 gives the distribution of the patients according
to their pretreatment levels and the presence or absence
of residual tumour. In 144 patients with a pretreatment
CEA value > 4.9 jug/1 the course of posttreatment CEA
was known. Among these, 20 patients had residual tu-
mour. It will be noted that posttreatment CEA dimin-
ished in 2 patients within 100 days until it was below 5.0
Mg/1 (even below 3.0 Mg/1) in spite of residual tumour.
These results indicate the possibility of 'false' decrease
of posttreatment CEA.
Association offall of posttreatment CEA with tumour-
free period
Figure 5 concerns patients with pretreatment values
> 4.9 Mg/1 and without residual tumour after primary
treatment. Fall of serial posttreatment CEA values did
not provide any information regarding the duration of
the subsequent tumour-free period. From this graph it
is apparent that no predictive information is obtained if
serial CEA levels decrease.
Association of rise of CEA with subsequent tumour-free
period
The bottom line in Figure 6 is an actuarial plot of tu-
mour-free periods following a rise of posttreatment CEA.























Fig. 5. The association of fall of posttreatment CEA with subse-
quent tumour-free period. See legend to figure 1 and sec-
tion Patients and Methods for explanation of presentation.
P =0.25.
In the no fall curves, time is measured from the end of the
indicated interval.
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Fig. 6. The association of rise of CEA with subsequent tumour-
free period. See legend to figure 1 and section Patients
and Methods for furtther explanation of presentation.
P < 1(T8.
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Fig. 7. Relationship of rise of CEA and time from primary the-
rapy. The straight right part of the curve indicates that
from 1300 days post therapy the fraction of patients
with no rise of CEA remained stationary.
1.00 r
tients with a positive lead time (i.e. CEA rise prior to de-
tection of recurrence). The greatest lead time was 625
days. A fraction of 0.50 of patients showed clinical indi-
cations of recurrence within approximately 125 days
after CEA rise. On the other hand, as can be seen from
the intersection with the vertical axis, a fraction of about
0.22 showed first signs of recurrence at the same time
that CEA started to rise. A fraction of 0.30 of patients
with CEA rise did not show recurrence. For comparison
the upper lines are shown referring to tumour-free
periods after a given period in which no rise of CEA
(i.e. CEA decrease or CEA no fall) was observed. For
example, a fraction of 0.76 of 139 patients, showing no
rise of CEA during a posttreatment period of 500 days,
were still tumour-free after a further period of 1000
days. Comparison of the data represented by the bottom
line and those presented by the upper lines demonstrates
that a rise of posttreatment CEA as an indication of
recurrence has a prognostic value at a highly signi-
ficant level. We were therefore interested in defining
the minimum follow-up by CEA assays necessary for in-
dication of recurrence. Figure 7 shows that 1300 days
after primary treatment no new increase of CEA was ob-
served in our patients. (The last recurrence was observed
at day 1611).
Thus, the risk of developing recurrence after a 1300 days
period of surveillance without increase of posttreatment
CEA can be considered as minimal.
Distribution of lead times in local and distant recurrences
Figure 8 shows a cumulative plot of differences in time of
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Fig. 8. Cumulative plot of time of CEA rise relative to time of
local recurrence (n = 18). Point 0 is time of diagnosis of
recurrence. At the negative site (left) of 0 are plotted the
positive lead times.
of local recurrence without signs of distant metastases at
the time. Positive lead time was observed in a fraction of
0.25 of the patients. On the other hand detection of local
recurrence preceded a CEA rise in a fraction of 0.50 of the
patients (highest negative lead time was 585 days). A
similar distribution of lead times was found in patients
with distant metastases (fig. 9). In a fraction of 0.43 of
patients the diagnosis of recurrence was preceded up to
625 days by CEA rise. In a fraction of 0.10 the interval
between CEA rise and diagnosis of recurrence was at
least 275 days, although in a fraction of 0.39 detection
of recurrence preceded a rise of CEA (maximal negative
lead time 430 days).
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Fig. 9. Cumulative plot of time of CEA rise relative to time of
distant recurrence (n = 52). Point 0 is time of diagnosis
of recurrence. At the negative site (left) of 0 are plotted
the positive lead times.
Discussion
Pretreatment CEA
A role for pretreatment CEA in predicting prognosis is
suggested by several data: There is a tendency towards
higher fractions of patients with increased CEA from
Dukes A to Dukes C groups (2,11-14, see also tab. 1).
The Dukes classification is related to prognosis. We ob-
served that the high prognostic significance of pretreat-
ment CEA (fig. 2) was sharply reduced or even abolished
if posttreatment data such as presence of residual tumour
or pathological staging became available. Our finding that
CEA as a prognostic reference is not superior to staging
according to Dukes is in agreement with statements of
Beatty et al (15) ana Evans et al (1), but contradictory
to those ofHerrera et al (16) and those of Wanebo et al
(2). CEA has prognostic significance only in inoperable
patients.
Decrease of pretreatment CEA to normal is not conclu-
sive for cure (tab. 2). To our knowledge only Mach et al
(17) have given evidence for the existence of 'false de-
crease' of pretreatment CEA.
Figure 2 shows that a considerable fractions of patients
with elevated pretreatment CEA have recurrence-free
periods post therapy up to 2000 days. Thus, elevated pre-
treatment levels, even if above 20.0 ìg/l, do not preclude
the possibility of curative treatment.
b. a rise of CEA, if defined by strict criteria, is highly
prognostic for recurrence,
c. the occurence of a 'false' rise must be taken into
account. Such a rise is transient and followed by a return
to baseline (15, 18-22).
The curves of figures 8 and 9 indicate that both positive
and negative lead times are possible and strongly suggest
that a recurrence without any rise of CEA is exceptional
(In disseminated breast cancer a different conclusion was
reached (24)). This rule seems to hold for both local and
distant recurrences. Earlier reports (25, 26,27) on pa-
tients with persisting low CEA values after detection of
recurrence can be explained by assuming insufficient
time of follow-up by CEA. The limited fraction of pa-
tients with positive lead time and data of figures 5 and 6
permit the following observations: a low or normal CEA
during follow-up is not a strong indication that the pa-
tient is free of recurrence. Serial CEA determinations
cannot replace physical examination and symptom re-
view, nor is the converse valid. Recurrence may be detec-
ted early in one individual patient by CEA and by physi-
cal examination in another. This finding is in agreement
with a statement by Sugarbaker et al (26). Thirdly, fol-
low-up by CEA can be restricted to about 1300 days (fig.
7) while continuing with physical checks.
The shape of the curves in figures 8 and 9 is related both
to frequency of physical examinations and sampling for
CEA. The intervals were not standardized. With less fre-
quent examinations, but shorter intervals of CEA tests,
the curve would have shifted to the left, resulting in a
higher mean value of positive lead time. In the reverse
case a higher mean value of negative lead time would have
been obtained. Although the precise shape of the curves
(figs. 8 and 9) is disputable, conclusions regarding the
prognostic function of CEA in detecting recurrence can
be made.
Local recurrence is the only type of tumour progression
which can be treated curatively. Some authors (21, 28)
have studied the potential of CEA rise for early detection
of local recurrence, hoping to increase in this way the be-
nefit of secondary surgery. Of all our patients with rising
CEA, a fraction of pprox. 0.05 had both local recurrence
and a minimal positive lead time of 200 days. This low
fraction is discouraging. Staab et al (21) presented varia-
tions of CEA suggesting that a slow rise is indicative for
local recurrence. This approach, however still awaits
statistical confirmation.
CEA and recurrence
Figures 5 and 6 give statistical evidence that
a. a decrease or stationary posttreatment CEA does not
provide any prognostic information as regards recurrence-
free period,
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